Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine

ABSTRACT Research progress over the past 20 years has yielded several experimental Ebola virus (EBOV) vaccine candidates, which were shown to be effective in nonhuman primates when given 28 days before a lethal challenge. Of these, the vesicular stomatitis virus (VSV)-vectored vaccine against EBOV (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gary Wong
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2019
Materias:	Ebola vaccine vesicular stomatitis virus Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/cc4d4dfa7ac14fefb4b974a9957f2471
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc4d4dfa7ac14fefb4b974a9957f2471
record_format	dspace
spelling	oai:doaj.org-article:cc4d4dfa7ac14fefb4b974a9957f24712021-11-15T16:22:11ZProgress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine10.1128/mBio.01597-192150-7511https://doaj.org/article/cc4d4dfa7ac14fefb4b974a9957f24712019-08-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01597-19https://doaj.org/toc/2150-7511ABSTRACT Research progress over the past 20 years has yielded several experimental Ebola virus (EBOV) vaccine candidates, which were shown to be effective in nonhuman primates when given 28 days before a lethal challenge. Of these, the vesicular stomatitis virus (VSV)-vectored vaccine against EBOV (VSV-EBOV) is unique at being able to induce rapid protection, with 100% survival achieved as soon as 7 days after EBOV challenge. In a recent mBio article, Menicucci et al. carried out a transcriptome analysis of host responses in monkeys immunized with VSV-EBOV from 28 to 3 days before challenge (A. R. Menicucci, A. Jankeel, H. Feldmann, A. Marzi, and I. Messaoudi, mBio 10:e00597-19, 2019, https://doi.org/10.1128/mBio.00597-19). It was found that surviving animals had a controlled innate immune response coupled with rapid adaptive immunity, but this was not detected in nonsurviving animals. These studies highlight the important role innate immunity plays in creating an antiviral state to restrict EBOV replication and ensuring enough time for the vaccine to induce an effective adaptive immune response.Gary WongAmerican Society for MicrobiologyarticleEbolavaccinevesicular stomatitis virusMicrobiologyQR1-502ENmBio, Vol 10, Iss 4 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ebola vaccine vesicular stomatitis virus Microbiology QR1-502
spellingShingle	Ebola vaccine vesicular stomatitis virus Microbiology QR1-502 Gary Wong Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
description	ABSTRACT Research progress over the past 20 years has yielded several experimental Ebola virus (EBOV) vaccine candidates, which were shown to be effective in nonhuman primates when given 28 days before a lethal challenge. Of these, the vesicular stomatitis virus (VSV)-vectored vaccine against EBOV (VSV-EBOV) is unique at being able to induce rapid protection, with 100% survival achieved as soon as 7 days after EBOV challenge. In a recent mBio article, Menicucci et al. carried out a transcriptome analysis of host responses in monkeys immunized with VSV-EBOV from 28 to 3 days before challenge (A. R. Menicucci, A. Jankeel, H. Feldmann, A. Marzi, and I. Messaoudi, mBio 10:e00597-19, 2019, https://doi.org/10.1128/mBio.00597-19). It was found that surviving animals had a controlled innate immune response coupled with rapid adaptive immunity, but this was not detected in nonsurviving animals. These studies highlight the important role innate immunity plays in creating an antiviral state to restrict EBOV replication and ensuring enough time for the vaccine to induce an effective adaptive immune response.
format	article
author	Gary Wong
author_facet	Gary Wong
author_sort	Gary Wong
title	Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
title_short	Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
title_full	Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
title_fullStr	Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
title_full_unstemmed	Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
title_sort	progress in elucidating potential markers and mechanisms of rapid protection conferred by the vsv-vectored ebola virus vaccine
publisher	American Society for Microbiology
publishDate	2019
url	https://doaj.org/article/cc4d4dfa7ac14fefb4b974a9957f2471
work_keys_str_mv	AT garywong progressinelucidatingpotentialmarkersandmechanismsofrapidprotectionconferredbythevsvvectoredebolavirusvaccine
_version_	1718426933037891584

Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine

Ejemplares similares